Healx
AI drug discovery (rare disease), Cambridge
AI-powered drug discovery and repurposing for rare diseases, clinical-stage pipeline. It raised $47m in its Series C in August 2024. It has 1 role open, 1 of them in the UK.
Backed by Atomico, Balderton Capital and R42 Group. Total raised ~$115m.
On the Home Office register of licensed visa sponsors.
- 67 daystypical age of an open role
- 1roles open for more than 60 days
- 1roles taken down since we started tracking
- 0%of roles list a salary
Open roles
1 live today- Salary not listed27 Aug 2026Apply
Open roles over time
Hiring momentum
Roles per weekAdded (by posting date)Closed (removed from the board)In the news (hover for headline)
Open roles by function
In the news
All 12 stories- Othercambridgeindependent.co.uk, 24 Jul 2026First patient is dosed in Healx HLX-4310 trial backed by Sunshine Project consortium
- OtherGlobeNewswire, 22 Jul 2026Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
- OtherThe Clinical Trial Vanguard, 22 Jul 2026Healx Doses First Patient in HLX-4310 Trial for Metastatic Osteosarcoma
- OtherGlobeNewswire, 22 Jul 2026Healx Announces First Patient Dosed in Phase 1/2 Trial to
- OtherBusiness Weekly, 21 Jul 2026Healx reveals first patient dosing in fight against rare bone cancer
- ExpansionBusiness Wire, 21 May 2026CAN Community Health Launches Healx Solutions to Expand Access in Specialty Therapy Services